<DOC>
	<DOCNO>NCT00916292</DOCNO>
	<brief_summary>The purpose study see FGF-1 safe apply topically surface wound .</brief_summary>
	<brief_title>Safety Study Topical Human FGF-1 Wound Healing</brief_title>
	<detailed_description>Dermal ulcer pose significant healthcare problem United States , ultimately affect 10-15 % approximately 20 million patient diabetes similar number patient chronic venous insufficiency . Dermal leg foot ulcer result compromise arterial inflow , microvascular perfusion venous outflow lead amputation unless vascular perfusion improve . FGF-1 topical administration offer possibility improve microvascular perfusion promote formation new blood vessel wound bed result enhance development granulation tissue accelerate healing .</detailed_description>
	<mesh_term>Diabetic Foot</mesh_term>
	<mesh_term>Foot Ulcer</mesh_term>
	<criteria>1 . Sign inform consent form prior initiation study procedure . Subjects must competent give write informed consent . 2 . Age must 18 75 year age . 3 . Female subject must postmenopausal sterilize , childbearing potential , breast feeding , serum pregnancy test negative . 4 . Subjects must willing change wind dressing daily demonstrate study personnel ability follow dress care instruction indicate Appendix . Subjects consider eligible enter study must sign informed consent form prior initiation study procedure . In event subject must withdraw rescreened study participation later date , new inform consent form must sign . Subjects must competent give write informed consent . 1 . Subjects receive radiation therapy , corticosteroid , immunosuppressive agent chemotherapy . 2 . Subjects , study entry , take systemic antibiotic . 3 . Subjects immunosuppressed . 4 . Subjects experience bacterial viral infection may otherwise febrile . 5 . Past history current presence type cancer ( except past history basal cell carcinoma limb treat ) . Subjects exist BCC exclude study . 6 . Life expectancy less 1 year . 7 . Active alcohol drug abuse within 6 month prior study entry . 8 . Screening liver function test 2.0 time upper limit normal . 9 . Serum creatinine â‰¥ 2.5 mg/dl . 10 . Hemoglobin A1c ( HgbA1c ) &gt; 10 % . 11 . Exposure investigational drug device participation investigational study within 30 day prior study entry . 12 . Any medical , social , geographical factor would make unlikely subject comply study procedure ( e.g. , alcohol abuse , lack permanent residence , severe depression , disorientation , distant location , history noncompliance ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>dermal ulcer</keyword>
</DOC>